Skip to main content
. 2017 Oct 6;8(55):94069–94079. doi: 10.18632/oncotarget.21578

Figure 4. Transfer of miR-21-silenced B cells ameliorates the clinical severity of EAE and inhibits pro-inflammatory cytokine expression.

Figure 4

(A) CD19+ B cells were purified by MACS from antagomiR-21-treated or negative-control-treated B6 mice on day 14 after EAE immunization; 1×107 purified B cells were then adoptively transferred into B6 EAE mice on days 1, 5 and 10 after immunization, and the EAE score was assessed daily. The mean clinical scores of the EAE mice are shown; the data represent one experiment and are presented as the mean ± SEM. (B) Serum was collected from mice as described in A on day 14 after EAE induction, and ELISA was performed to detect the expression levels of the cytokines IFN-γ and TNF-ɑ. The serum samples were collected from 3 mice per group, and the results are expressed as the mean ± SEM. *P < 0.05.

HHS Vulnerability Disclosure